Dose finding studies on flucytosine in patients with fungi in their urine

Satoshi Uno; Tadasu Takenaka; Yoshio Nishitani; Toshihide Hayashi; Kazuhiro Hata; Noriaki Ono; Masaya Tsugawa; Hiromi Kumon; Hiroyuki Ohmori; Katsuichi Nanba; Yoshikatu Kondoh; Teruhisa Ohashi; Shin Irie; Tetuzou Kaneshige; Hiroyuki Kawahara; Hiroyoshi Tanaka; Shouichi Yamamoto; Motoyoshi Takada; Daisuke Yamada; Toshihiko Asai; Yasuhiro Katayama; Teruaki Akaeda; Akihiro Mizuno; Noritaka Ishito; Nobuyuki Akazawa; Mikio Kishi; Ryouji Nasu; Naoki Mitsuhata; Shunji Hayata; Yasutomo Nasu; Toshiki Yamamoto; Takafumi Akagi; Masanobu Tanimura; Seiichi Kataoka; Yukitoshi Fujita; Yoshikazu Hirai; Yasuhiro Kanemasa; Yasuichi Saitoh

doi:10.11250/chemotherapy1953.40.1263

Dose finding studies on flucytosine in patients with fungi in their urine

Satoshi Uno, Tadasu Takenaka, Yoshio Nishitani, Toshihide Hayashi, Kazuhiro Hata, Noriaki Ono, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Yoshikatu Kondoh, Teruhisa Ohashi, Shin Irie, Tetuzou Kaneshige, Hiroyuki Kawahara, Hiroyoshi Tanaka, Shouichi Yamamoto, Motoyoshi Takada, Daisuke Yamada, Toshihiko AsaiYasuhiro Katayama, Teruaki Akaeda, Akihiro Mizuno, Noritaka Ishito, Nobuyuki Akazawa, Mikio Kishi, Ryouji Nasu, Naoki Mitsuhata, Shunji Hayata, Yasutomo Nasu, Toshiki Yamamoto, Takafumi Akagi, Masanobu Tanimura, Seiichi Kataoka, Yukitoshi Fujita, Yoshikazu Hirai, Yasuhiro Kanemasa, Yasuichi Saitoh

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.

Original language	English
Pages (from-to)	1263-1272
Number of pages	10
Journal	CHEMOTHERAPY
Volume	40
Issue number	10
DOIs	https://doi.org/10.11250/chemotherapy1953.40.1263
Publication status	Published - Oct 1992
Externally published	Yes

Keywords

flucytosine

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.40.1263

Cite this

Uno, S., Takenaka, T., Nishitani, Y., Hayashi, T., Hata, K., Ono, N., Tsugawa, M., Kumon, H., Ohmori, H., Nanba, K., Kondoh, Y., Ohashi, T., Irie, S., Kaneshige, T., Kawahara, H., Tanaka, H., Yamamoto, S., Takada, M., Yamada, D., ... Saitoh, Y. (1992). Dose finding studies on flucytosine in patients with fungi in their urine. CHEMOTHERAPY, 40(10), 1263-1272. https://doi.org/10.11250/chemotherapy1953.40.1263

Uno, S, Takenaka, T, Nishitani, Y, Hayashi, T, Hata, K, Ono, N, Tsugawa, M, Kumon, H, Ohmori, H, Nanba, K, Kondoh, Y, Ohashi, T, Irie, S, Kaneshige, T, Kawahara, H, Tanaka, H, Yamamoto, S, Takada, M, Yamada, D, Asai, T, Katayama, Y, Akaeda, T, Mizuno, A, Ishito, N, Akazawa, N, Kishi, M, Nasu, R, Mitsuhata, N, Hayata, S, Nasu, Y, Yamamoto, T, Akagi, T, Tanimura, M, Kataoka, S, Fujita, Y, Hirai, Y, Kanemasa, Y & Saitoh, Y 1992, 'Dose finding studies on flucytosine in patients with fungi in their urine', CHEMOTHERAPY, vol. 40, no. 10, pp. 1263-1272. https://doi.org/10.11250/chemotherapy1953.40.1263

@article{a830e11f5dc3430db9f309bd6b3bb8b5,

title = "Dose finding studies on flucytosine in patients with fungi in their urine",

abstract = "In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.",

keywords = "flucytosine",

author = "Satoshi Uno and Tadasu Takenaka and Yoshio Nishitani and Toshihide Hayashi and Kazuhiro Hata and Noriaki Ono and Masaya Tsugawa and Hiromi Kumon and Hiroyuki Ohmori and Katsuichi Nanba and Yoshikatu Kondoh and Teruhisa Ohashi and Shin Irie and Tetuzou Kaneshige and Hiroyuki Kawahara and Hiroyoshi Tanaka and Shouichi Yamamoto and Motoyoshi Takada and Daisuke Yamada and Toshihiko Asai and Yasuhiro Katayama and Teruaki Akaeda and Akihiro Mizuno and Noritaka Ishito and Nobuyuki Akazawa and Mikio Kishi and Ryouji Nasu and Naoki Mitsuhata and Shunji Hayata and Yasutomo Nasu and Toshiki Yamamoto and Takafumi Akagi and Masanobu Tanimura and Seiichi Kataoka and Yukitoshi Fujita and Yoshikazu Hirai and Yasuhiro Kanemasa and Yasuichi Saitoh",

year = "1992",

month = oct,

doi = "10.11250/chemotherapy1953.40.1263",

language = "English",

volume = "40",

pages = "1263--1272",

journal = "Chemotherapy",

issn = "0009-3165",

number = "10",

}

TY - JOUR

T1 - Dose finding studies on flucytosine in patients with fungi in their urine

AU - Uno, Satoshi

AU - Takenaka, Tadasu

AU - Nishitani, Yoshio

AU - Hayashi, Toshihide

AU - Hata, Kazuhiro

AU - Ono, Noriaki

AU - Tsugawa, Masaya

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Nanba, Katsuichi

AU - Kondoh, Yoshikatu

AU - Ohashi, Teruhisa

AU - Irie, Shin

AU - Kaneshige, Tetuzou

AU - Kawahara, Hiroyuki

AU - Tanaka, Hiroyoshi

AU - Yamamoto, Shouichi

AU - Takada, Motoyoshi

AU - Yamada, Daisuke

AU - Asai, Toshihiko

AU - Katayama, Yasuhiro

AU - Akaeda, Teruaki

AU - Mizuno, Akihiro

AU - Ishito, Noritaka

AU - Akazawa, Nobuyuki

AU - Kishi, Mikio

AU - Nasu, Ryouji

AU - Mitsuhata, Naoki

AU - Hayata, Shunji

AU - Nasu, Yasutomo

AU - Yamamoto, Toshiki

AU - Akagi, Takafumi

AU - Tanimura, Masanobu

AU - Kataoka, Seiichi

AU - Fujita, Yukitoshi

AU - Hirai, Yoshikazu

AU - Kanemasa, Yasuhiro

AU - Saitoh, Yasuichi

PY - 1992/10

Y1 - 1992/10

N2 - In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.

AB - In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.

KW - flucytosine

UR - http://www.scopus.com/inward/record.url?scp=0026564024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026564024&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.1263

DO - 10.11250/chemotherapy1953.40.1263

M3 - Article

AN - SCOPUS:0026564024

VL - 40

SP - 1263

EP - 1272

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - 10

ER -

Dose finding studies on flucytosine in patients with fungi in their urine

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this